<DOC>
	<DOCNO>NCT00754689</DOCNO>
	<brief_summary>The primary objective study demonstrate superiority rimonabant/metformin combination Glycosylated Hemoglobin 1c ( A1C ) reduction correspond single agent metformin rimonabant alone patient type 2 diabetes mellitus 9 month . The secondary objective investigate effect rimonabant/metformin combination reduce fasted plasma glucose , body weight triglyceride , raise High Density Lipoprotein Cholesterol ( HDL-C ) comparison metformin 9 month . Another objective evaluate safety rimonabant combination metformin period 52 week .</brief_summary>
	<brief_title>Study Rimonabant/Metformin Combinations Investigate Diabetes ( Blood Sugar ) Control Patients With Type 2 Diabetes</brief_title>
	<detailed_description>The duration per patient 65 week : 1 - 2 week screen , 52 week double blind treatment , 75 day post last dose . This study end patient last patient treat least 9 month .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>History type 2 diabetes mellitus diagnose prior screen visit 1 ( ADA criterion ) Patients must use oral injectable glucose lower medication least 12 week prior screen visit establish stable , comparable baseline A1C assessment patient A1C ≥7.0 % ≤10.0 % Fasted plasma glucose screen visit ≤260 mg/dL ( 14.44 mmol/L ) Treatment antidiabetic oral agent , injectable antidiabetic agent within 12 week prior screen visit In 3 month prior screen visit , use antiobesity agent drug weight loss , administration systemic corticosteroid 7 day Presence severe medical psychological condition , opinion investigator , would compromise patient 's safe participation include uncontrolled serious psychiatric illness major depression within last 2 year , history severe psychiatric disorder Presence history cancer within past five year Pregnant breastfeed woman , woman childbearing potential protected effective method birth control The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Rimonabant/metformin combination</keyword>
</DOC>